Recently, Lixisenatide, a GLP1 receptor agonist, showed a neuroprotective effect in a phase 2, double-blind, randomized, placebo-controlled trial with 156 PD patients (Meissner et al. 2024). The gene discussed is GLP1R; the disease is Parkinson disease.